Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 11 2020
Historique:
received: 08 05 2020
accepted: 11 05 2020
pubmed: 21 5 2020
medline: 10 4 2021
entrez: 21 5 2020
Statut: ppublish

Résumé

On June 13 to 14, 2019, the American Society for Radiation Oncology and the Radiological Society of North America convened a workshop on the treatment of oligometastatic disease in Washington, DC. The workshop was initiated for several reasons. First, oligometastatic disease is of increasing academic and community interest and has been identified by the American Society for Radiation Oncology membership as a top research priority. Second, emerging imaging and diagnostic technologies are more readily defining and detecting oligometastatic disease, making contemporary discussion of oligometastatic disease especially relevant. Third, radiosurgery and radiation in general are theorized to be ideal noninvasive therapy for the treatment of oligometastatic disease. Finally, innovations in targeted therapy and immune therapy have the potential to reverse widely disseminating disease into an oligometastatic state. The workshop was organized into 2 keynote addresses, 6 scientific sessions, and 3 group discussions during an end-of-workshop breakout session. New scientific work was presented in the form of 4 oral presentations and a poster session. Workshop participants were charged with attempting to answer 3 critical questions: (1) Can we refine the clinical and biological definitions of oligometastatic disease; (2) how can we better treat oligometastatic disease; and (3) what clinical trials are needed? Here, we present the proceedings of the workshop. The clinical implications of improved treatment of oligometastatic disease are enormous and immediate. Radiation oncology and diagnostic radiology should rightly be at the forefront of the characterization and treatment of oligometastatic disease. Focused effort is required so that we can translate current efforts of large numbers of studies with few patients to larger studies of larger impact.

Identifiants

pubmed: 32434040
pii: S0360-3016(20)31142-1
doi: 10.1016/j.ijrobp.2020.05.018
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Radiopharmaceuticals 0

Types de publication

Congress

Langues

eng

Sous-ensembles de citation

IM

Pagination

539-545

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

James B Yu (JB)

Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut. Electronic address: james.b.yu@yale.edu.

Kristy K Brock (KK)

Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.

Allison M Campbell (AM)

Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.

Aileen B Chen (AB)

Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.

Roberto Diaz (R)

Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida.

Freddy E Escorcia (FE)

National Cancer Institute, Bethesda, Maryland.

Gaorav Gupta (G)

Department of Radiation Oncology, University of North Carolina Medical School, Chapel Hill, North Carolina.

William T Hrinivich (WT)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, Maryland.

Sabrina Joseph (S)

American Society for Radiation Oncology, Arlington, Virginia.

Mark Korpics (M)

Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois.

Benjamin E Onderdonk (BE)

Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois.

Neeta Pandit-Taskar (N)

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.

Bradford J Wood (BJ)

National Cancer Institute, Bethesda, Maryland.

Wendy A Woodward (WA)

Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH